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Abstract
Background: Statins effectively lower total and plasma LDL-cholesterol, but the magnitude of decrease varies among
individuals. To identify single nucleotide polymorphisms (SNPs) contributing to this variation, we performed a combined
analysis of genome-wide association (GWA) results from three trials of statin efficacy.
Methods and Principal Findings: Bayesian and standard frequentist association analyses were performed on untreated and
statin-mediated changes in LDL-cholesterol, total cholesterol, HDL-cholesterol, and triglyceride on a total of 3932 subjects
using data from three studies: Cholesterol and Pharmacogenetics (40 mg/day simvastatin, 6 weeks), Pravastatin/
Inflammation CRP Evaluation (40 mg/day pravastatin, 24 weeks), and Treating to New Targets (10 mg/day atorvastatin, 8
weeks). Genotype imputation was used to maximize genomic coverage and to combine information across studies.
Phenotypes were normalized within each study to account for systematic differences among studies, and fixed-effects
combined analysis of the combined sample were performed to detect consistent effects across studies. Two SNP
associations were assessed as having posterior probability greater than 50%, indicating that they were more likely than not
to be genuinely associated with statin-mediated lipid response. SNP rs8014194, located within the CLMN gene on
chromosome 14, was strongly associated with statin-mediated change in total cholesterol with an 84% probability by
Bayesian analysis, and a p-value exceeding conventional levels of genome-wide significance by frequentist analysis
(P=1.8610
28). This SNP was less significantly associated with change in LDL-cholesterol (posterior probability=0.16,
P=4.0610
26). Bayesian analysis also assigned a 51% probability that rs4420638, located in APOC1 and near APOE, was
associated with change in LDL-cholesterol.
Conclusions and Significance: Using combined GWA analysis from three clinical trials involving nearly 4,000 individuals
treated with simvastatin, pravastatin, or atorvastatin, we have identified SNPs that may be associated with variation in the
magnitude of statin-mediated reduction in total and LDL-cholesterol, including one in the CLMN gene for which statistical
evidence for association exceeds conventional levels of genome-wide significance.
Trial Registration: PRINCE and TNT are not registered. CAP is registered at Clinicaltrials.gov NCT00451828
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Statins are the most widely prescribed drug class for the
prevention of cardiovascular disease (CVD) and act primarily by
lowering plasma LDL-cholesterol (LDLC) [1,2,3]. Statin-induced
reductions of LDLC vary among individuals and this may reflect
genetic differences [4,5]. Variation in LDLC response has been
associated with several loci involved in cholesterol and lipoprotein
metabolism including APOE, HMGCR, PCSK9, LDLR and APOB,
but these account for only a small portion of the variance in LDLC
response [4,6,7]. Recently, a common nonsynonymous SNP in the
gene encoding the cellular motor protein KIF6 was found to be
associated with both increased CVD risk and greater statin-related
CVD risk reduction but not with lipid or lipoprotein response to
statins [8].
Genome-wide association (GWA) studies provide a more
comprehensive approach for identifying genetic loci associated
with statin response. GWA studies have identified many loci
associated with plasma lipid and lipoprotein traits, including
several not previously known to be related to lipoprotein
metabolism [9,10,11,12]. However, there is to date only one
report of GWA of lipid response to statin treatment [13]. This
involved ,2,000 participants in the Treating to New Targets
study who were treated with atorvastatin 10 mg/day for eight
weeks. However, no SNPs were identified from this analysis that
were convincingly associated with atorvastatin-mediated lipid
changes (P.1610
27 for all associations) [13].
The power of GWA studies to identify and convincingly
document associations of SNPs with complex traits has been
greatly enhanced by generating large data sets from combined
studies [9,10,14,15,16]. Motivated by this, we performed a
combined analysis of the three statin GWA studies currently
available to us: TNT and two previously-unpublished trials. To
deal with the fact that different studies typed different SNPs, we
used imputation methods [17,18] to infer genotypes for approx-
imately 2.5 million HapMap SNPs in all three studies [17,18,19].
To allow for systematic differences among the three statin trials,
we normalized phenotype measurements for each individual
relative to other individuals within the same study before
performing a fixed-effects combined-analysis. In addition we used
a novel Bayesian statistical approach, with a bivariate phenotype
derived from pre-statin and post-statin phenotype levels, to
simultaneously identify both statin-independent and statin-
dependent SNP associations.
Methods
Study populations
The 3,936 Caucasian individuals in these analyses had
participated in one of three statin trials, all of which have been
described previously [5,20,21].The Cholesterol and Pharmacoge-
netics (CAP) trial involved 944 healthy volunteers, 609 of whom
were Caucasian, treated for six weeks with simvastatin 40 mg/day
at two study sites (University of California, Los Angeles and San
Francisco General Hospital) [5]. Blood samples were collected for
lipid and lipoprotein analysis twice prior to treatment (screen and
entry visits) and twice while on treatment (4 and 6 weeks). There
were no significant differences between the two pretreatment
measurements or the two post-treatment measurements, and
therefore these values were averaged to obtain pre-treatment and
post-treatment values, respectively.
The Pravastatin Inflammation/CRP Evaluation (PRINCE)
study enrolled 1702 individuals with no history of prior heart
disease and LDLC .135 mg/dL, and 1182 individuals with
known cardiovascular disease (CVD)–defined as previous myo-
cardial infarction, stroke, or coronary revascularization from 1143
clinical sites across the United States (#4 participants/site).
Participants were treated with 40 mg/day pravastatin for twelve
weeks [20]. Individuals with no history of prior heart disease were
treated as part of a randomized controlled double blind study and
those with CVD history were provided with open label
pravastatin. Our analyses were not stratified by treatment group
assignment. Laboratory analyses were performed on blood
samples collected once prior to treatment, and once following
twelve weeks of treatment. 1056 participants also provided a blood
sample following twenty-four weeks of treatment. For those
individuals who provided two post-treatment samples, these values
were averaged to obtain a single post-treatment value. DNA
samples were collected from 1536 PRINCE participants including
1362 that were self-identified as Caucasian [22].
The Treating to New Targets (TNT) study followed 10,001
patients with clinically evident CHD and with LDLC 130 to
250 mg/dL at screen and #130 mg/dL following 4 weeks on
treatment [21]. CHD was defined by previous myocardial
infarction, previous or current angina with objective evidence of
atherosclerosis, or history of coronary revascularization. Lipids
were analyzed using blood samples collected once prior to
treatment and once following eight weeks of treatment. Individuals
with evidence of poor compliance, assessed on the basis of LDLC
.130 mg/dL following treatment for 4 weeks, were excluded
from analysis. 2,092 patients of European ancestry were selected
for inclusion in whole genome genotyping and these included 523
individuals who had coronary events during the trial (‘‘cases’’) and
1,569 selected ‘‘control’’ individuals who did not. Controls were
matched 3:1 to cases by ancestry, age, gender, smoking, diabetes,
hypertension, baseline glucose, and screening LDLC [13]. Of the
selected individuals, genotyping data was successfully obtained on
1,976 (call rate $80%).
Approvals for each study were obtained from the Institutional
Review Boards at participating institutions for that study and each
participant signed a statement of informed consent that provided
permission for samples to be used in future genomic studies. All
three studies measured LDLC, total cholesterol (TC), HDL-
cholesterol (HDLC) and triglycerides (Tg) in laboratories certified
by the Centers for Disease Control and Prevention (Atlanta,
Georgia).
Genotyping and Genotype Imputation
Whole-genome genotypes for CAP and PRINCE participants
were measured in two stages (henceforth referred to as Stage I and
Stage II). In Stage I, 304 CAP and 675 PRINCE participants were
genotyped for 314,621 single nucleotide polymorphisms (SNPs)
selected to tag common genomic variation in Caucasians
(HumanHap300 bead chip, Illumina, San Diego, CA). These
SNPs were derived from Phase I+II of the International HapMap
Project (www.hapmap.org) to tag common genomic variation
across individuals of European decent. This platform provides
genomic coverage in Caucasians of all Phase I+II loci of 91% for
an r
2 threshold $0.5 and 80% for an r
2 threshold $0.8 [23]. Our
analysis of genotyping quality, using ,18,000 SNPs contained on
the HumanHap300 bead chip, and a separate Human-1 (109,000
sites) bead chip showed a genotyping concordance rate of 99.97%.
In Stage II, 290 CAP and 687 PRINCE samples were
genotyped. This included 280 CAP and 652 PRINCE samples
(N=932) that were genotyped at 620,901 sites using the
HumanQuad610 bead chip (Illumina), which is also designed to
tag common variation within individuals of European ancestry,
and a partially-overlapping set of 292 CAP and 634 PRINCE
Genomics of Statin Response
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iSelect chip (N=926). The average call rate for stage II
genotyping was 99.8%. Four samples were excluded from further
analysis based on gender discrepancies. Concordance between
SNPs on the HumanQuad610 bead chip and the custom-made
iSelect chip exceeded 99.5%.
Genotyping in TNT participants was performed as described
previously [9,13]. Genotypes were assessed for 322,185 SNPs
using the Perlegen platform (Perlegen, Mountain View, CA).
Homozygous sites and SNPs with call rate ,80% were eliminated
from analysis, leaving 291,988 SNPs. Of the 2092 participants
selected for analysis based on clinical characteristics, genotyping
was performed on the 1984 with sufficient quantity and quality
DNA. Of these, genotyping on eight individuals was omitted from
analysis due to sample mishandling. For the 1976 remaining
samples, sample call rates were all .91% and the average SNP
call rate was 97.9%.
We used the genotype imputation software BIMBAM [18,19] to
infer genotypes for each individual at the approximately 2.5
million SNPs typed in the HapMap (phase II) CEU parents [23].
Imputation procedures rely on the patterns of correlation among
typed and untyped SNPs inferred from HapMap individuals to
estimate genotypes at the untyped SNPs in each individual.
Imputation has the benefits of both maximizing genomic coverage
and facilitating combined analyses of studies involving different
genotyping platforms. All analyses were limited to Caucasians.
Statistical Analysis
We analyzed data from each of four phenotypes (LDLC, TC,
Tg and HDLC) separately. For each individual there are two
measures of each normalized phenotype: one reflecting levels pre-
statin exposure (baseline, X), and one reflecting levels post-
exposure (on study, Y). The values of X and Y are derived from
extensive normalization procedures designed to eliminate the
potential for false positive associations due to systematic differences
among studies (see below). However, it may aid interpretation of
methods and results to note that in practice X is approximately the
log of the pre-statin measure and Y is approximately the log of the
post-statin measure (both centered to have mean 0).
In brief, our analyses aim to identify SNPs that are associated
with the bivariate outcome (X,Y), and to distinguish between SNPs
that affect both X and Y in the same way (which we term ‘‘statin-
independent associations’’) and SNPs that affect X and Y
differently (‘‘statin-response associations’’). (Although this defini-
tion of statin-response associations may seem natural, there are
some issues with this definition that deserve attention, as we return
to in the discussion.) To do this it is convenient to reparameterize
(X,Y) in terms of the derived ‘‘sum’’ (S) and ‘‘difference’’ (D)
phenotypes, S=Y+X and D=Y2X. Because of the 1-1
correspondence between (X,Y) and (S,D), SNPs will be associated
with (X,Y) if and only if they are associated with (S,D). But the
(S,D) parameterization is convenient because i) statin-response
associations are exactly those SNPs that are associated with D, and
ii) S and D are uncorrelated.
For each SNP and phenotype, we assessed the fit of four
different models: H0, the null model that the SNP is associated
with neither S nor D; HS, the SNP is associated with S only; HD,
the SNP is associated with D only; HS+D, the SNP is associated
with both S and D. Note that HD and HS+D correspond to statin-
response associations, whereas HS corresponds to statin-indepen-
dent associations. One might expect many previously-reported
associations between genetic variants and lipid phenotypes to fall
into this last category, providing a helpful check of the consistency
of our results with previous lipid studies not involving statin
exposure. Our overall analytic strategy is to use the fits of these
models to identify SNPs with strong evidence for association with
the bivariate outcome (S,D) (i.e. against the null H0), and then
among these most associated SNPs to assess the evidence for a
statin-response association (HD and HS+D) vs. a statin-independent
association (HS).
This bivariate approach is motivated by the expectation that
many genetic variants associated with D will also be associated
with S (since to be associated with D but not S a variant would
have to have exactly opposite effects on Y and X). For these variants,
the support for HS+D should generally be greater than the support
for HD or HS alone, and so consideration of S and D
simultaneously should improve power to detect these kinds of
associations. Note that, in particular, this includes SNPs that are
associated with post-statin phenotype (Y) but not pre-statin
phenotype (X), since these SNPs will be associated with both S
and D; similarly for SNPs associated with X but not Y. In principle
it would be possible, and probably beneficial, to consider these two
particular scenarios explicitly, rather than simply including them
in a general search for associations with S and D as we do here.
However, the correlation between X and Y complicates this
analysis, and so we do not pursue it here.
To assess the relative support for the models H0,H S,H D, and
HS+D, we used Bayesian methods [18,24,25], which have
advantages over standard frequentist approaches in this context
(reviewed in [24]). For example, from a p-value alone it is difficult
to quantify how confident one should be that a given SNP is truly
associated with phenotype (e.g. is an association with a p-value of
10
28 more likely to be real or a false positive?). In contrast
Bayesian methods allow one to assess this confidence directly by
providing a posterior probability of association for each SNP. In
addition, Bayesian methods can be used to formalize ideas that
may be used informally in interpreting the results of frequentist
analyses: for example, here we use them to formalize the idea that
we may be less skeptical about an observed association with D if it
is also accompanied by an association with S.
Our Bayesian analysis involves two steps: first compute a Bayes
Factor (BF) for each of the models H0,H S,H D, and HS+D, and
then combine these BFs with prior probabilities on the models to
compute the posterior probability on each model. We now
describe each of these steps in more detail.
The BF for each model is given by the ratio of the probability of
the observed association data under that model to its probability
under H0, and provides a natural measure of the strength of the
support in the data for that model. For example, a BF of 100
indicates that the association data are 100 times more likely under
that model than under the null model. The BF for H0 is, by
definition, 1. We computed the remaining BFs as follows. Let BFS
denote the BF for association with the univariate outcome S,
computed using the method from Servin and Stephens [18], and
BFD denote the BF for association with the univariate phenotype
D. Then the BFs for models H0,H S,H D and HS+D are 1, BFS,
BFD and BFD xB F S, assuming independence of S and D.
Intuitively this approach highlights not only SNPs with strong
associations with S (large BFS) or with D (large BFD), but also
SNPs with moderate associations with both S and D (large BFS x
BFD); this is the main difference between our analysis and a more
standard univariate analysis.
To compute the univariate Bayes Factors BFS and BFD we used
the prior D2 from Servin and Stephens [18]. This prior allows for
both an additive effect (a), and a dominance effect (d) at each SNP,
with the expected size of these two effects being controlled by
hyperparameters sa and sd respectively. To put the majority of
weight on near-additive models, while still allowing for dominant/
Genomics of Statin Response
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can be sensitive to choice of sa we averaged results over multiple
values for sa, as suggested in Servin and Stephens [18] and
Stephens and Balding [24]. Specifically we used sa=0.05, 0.075,
0.1, 0.125, 0.15, 0.2, 0.4 (with equal weight on each). We
computed BFD and BFS using the genotype and phenotype data
from all individuals combined, and the software BIMBAM and its
ability to compute combined BFs from summary data on each
study, with posterior mean genotypes at imputed genotypes [19].
This corresponds to assuming that each SNP has the same effect in
all studies, and thus to performing a ‘‘fixed-effects’’ combined
analysis.
The posterior probabilities on each of the models H0,H S,H D,
and HS+D is then computed by combining the BFs with a prior
probability distribution on models. Specifically, the posterior
probability for each model is computed by multiplying the BF for
each model by the model’s prior probability, and then normalizing
the four resulting products to sum to 1, so that the posterior
probabilities on the 4 models sum to 1. In symbols, the posterior
probability for model i is given by posteriori =B F i 6 priori/
Sj BFj 6 priorj. We used the prior probability distribution:
Pr(H0)=1210
24, Pr(HS)=0.9610
24, Pr(HD)=0.01610
24,
Pr(HS+D)=0.09610
24. These prior probabilities were chosen to
i) place overall prior 10
24 on any kind of association for each SNP
with a given phenotype, in line with previous suggestions
[24,26,27]; ii) be substantially more skeptical about associations
with D than with S (overall prior on being associated with
D=10
25, compared with approximately 10
24 on S), and iii) be
less skeptical about an association with D if it is also accompanied
by an association with S. Posterior probabilities can be sensitive to
this choice of prior, particularly posterior probabilities that are not
very close to 0 or 1; see Discussion for more on sensitivity. The
posterior probabilities on models summarize the overall support
for each model, taking account of both the association data and
prior beliefs regarding the relative plausibility of the four models.
Using these posterior probabilities it is straightforward to assess the
overall evidence against the null hypothesis H0 (using the sum of
the posterior probabilities on HS,H D and HS+D), and furthermore
to partition this overall evidence into evidence for statin-
independent associations (posterior probability on HS) vs. statin-
response associations (sum of the posterior probabilities on HD and
HS+D).
To allow our results to be more easily compared with standard
frequentist analyses, we also used linear regression with S (and
respectively D) as the response variable, assuming an additive
genetic model at each SNP, to compute p-values for each SNP
against the null hypothesis that the SNP is unassociated with S
(and respectively D). We report p-values without adjustment for
multiple comparisons.
To deal with systematic differences in study population and
protocols, we normalized phenotype measurements within each
study. Normalized phenotypes for LDLC, TC, Tg and HDLC
were derived from raw pre-statin and post-statin measurements
following a four-step procedure. First, to limit the influence of
outliers, pre-statin and post-statin measurements were rank
transformed to a standard normal distribution within each data
set (CAP-Stage I, CAP-Stage II, PRINCE-Stage I; PRINCE-Stage
II; TNT). Second, derived sum and difference phenotypes (S and
D above) were computed from these rank-transformed values.
Next, values of S and D were corrected for covariates (log(BMI),
age, sex, and smoking status) within each dataset using ordinary
least squares regression. Finally, covariate-corrected values of S
and D were again rank transformed to normal distributions within
each dataset (note that any induced non-zero correlation between
the transformed S and D was always negligibly small). We note
that within each study the logs of each of the raw lipid measures
(both pre- and post- statin) are approximately normally distribut-
ed, and so the end result of this extensive normalization is similar
to (but not identical to) what would have been obtained by the
simpler approach of working with the log-transformed phenotype
values, and not performing the rank transformations to normal
distributions. We used the rank (rather than log) transformations
both to limit the effects of any deviations from normality (e.g.
outliers) in the log-transformed phenotypes, and, more important-
ly, to ensure that there are no distributional differences in tested
response variables among studies, so that any differences in allele
frequencies among the study samples will not cause spurious
associations.
Results
The characteristics of the three study populations are described
in Table 1. Although there are clear differences in clinical
characteristics across these populations, our normalization steps
should have ensured that systematic differences will not cause false
positive associations. However, cryptic population stratification
within studies could still cause spurious associations [28]. To assess
this, we compared the overall distribution of p-values for each
Table 1. Description of Study Populations.
PARC Populations
CAP PRINCE TNT
N 592 1360 1976
Gender, N males 313 (52.7%) 1044 (76.9%) 1622
(82.1%)
Age 54.4612.7 64.7613.0 62.468.3
BMI 27.765.5 29.065.3 29.064.6
Primary CVD (# subjects) 0 (0%) 843 (61.9%) 486 (24.6%)
Smoking (# subjects) 81 (13.6%) 183 (13.4%) 367 (18.6%)
Systolic BP 123.1616.8 133.4617.3 132.3617.3
Diastolic BP 70.769.8 79.0610.1 77.969.6
Total Cholesterol
Untreated 212.2635.1 215.3638.6 245.2629.1
Treated 153.4627.1 173.5636.2 174.2622.5
Change 258.861.0 241.860.8 271.160.5
LDLC
Untreated 133.0631.7 131.6629.1 161.8622.8
Treated 76.8622.5 97.7626.6 97.4616.0
Change 256.260.9 233.860.6 264.460.4
Triglyceride
Untreated 127.7666.9 200.36131.9 208.7697.1
Treated 104.4665.1 165.16116.6 156.4671.5
Change 223.761.8 235.362.6 252.461.4
HDLC
Untreated 53.8616.3 36.7610.3 46.8610.4
Treated 56.0617.0 38.5610.6 45.7610.0
Change 2.360.2 1.860.2 21.160.1
Abbreviations: CAP, Cholesterol and Pharmacogenetics trial; PRINCE, Pravastatin
Inflammation/CRP Evaluation trial; TNT, Treating to New Targets trial.
doi:10.1371/journal.pone.0009763.t001
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HDLC) with a uniform distribution. QQ plots (Figure S1) showed
generally good agreement except in the tail where deviations are
expected due to genuine associations. Genomic control inflation
factors ranged from 0.99 to 1.03 [29]. In addition, preliminary
analyses of the CAP and PRINCE studies that used Principal
Components Analysis (PCA) to correct for latent population
structure [30] produced similar results to analyses without PCA
correction (results not shown). Thus cryptic population stratifica-
tion does not appear to have a substantive impact on association
results in this case.
Table 2 shows regions harboring SNPs that were most strongly
associated with sum and/or difference phenotypes from our
analysis. This table includes all regions that contained a SNP with
.50% posterior probability of being genuinely associated with a
phenotype (i.e. ,50% posterior probability assigned to H0), and
associations are presented for the SNP within each region that
demonstrated the strongest evidence for association. More
comprehensive results are provided in Tables S1, S2, S3, S4,
and S5.
The majority of these putative associations appear to be
independent of statin treatment: 8 of the 11 have #4% probability
of being associated with the difference phenotype D (with or
without an accompanying association with the phenotype sum, S).
Of these 8 loci, five involve previously-reported associations that
have been robustly replicated: HDLC associations with SNPs in or
near the genes encoding cholesteryl ester transfer protein (CETP),
hepatic lipase (LIPC), and lipoprotein lipase (LPL); triglyceride
associations within the region containing apolipoprotein A5,
APOA5; and an LDLC association with SNPs located in the
CELSR2/PSRC1/SORT1 region of chromosome 1 [11,16,31]. Of
the other 3 statin-independent associations, the association of
triglyceride with rs9644568, located near LPL, and rs1883025,
located in ABCA1, seem the most likely to be genuine, based on the
known functions of these genes [32,33].
Our analyses also identified associations with the statin-
mediated difference trait. The strongest signal for such an
association was between statin-induced change in TC and SNPs
within introns 1–2 of the gene encoding calmin (CLMN). This
region of chromosome 14 has not been previously related to lipid
or lipoprotein traits. Multiple SNPs in this region showed
association with this trait in both Bayesian and Frequentist
analyses (Figure 1). The most strongly-associated SNP was
rs8014194. Our Bayesian method assessed this SNP to have an
84% posterior probability of being genuinely associated with
statin-mediated change in TC (77% probability of association with
both D and S; 7% probability of association with D alone).
Consistent with this high posterior probability, the frequentist test
Table 2. Top variants associated with difference or sum traits for LDLC, total cholesterol, triglyceride, or HDLC.
SNP Posterior Probability P-value MAF* Chr Nearest Genes
H0 HS HD H(S+D) Sum Diff Gene Symbols (Distance from variant, kb)
Total Cholesterol
rs8014194 0.16 ,0.01 0.07 0.77 0.06 1.9610
28 0.24
0.24/0.24/0.25
14 CLMN (0) FLJ45244 (74) DICER1 (97)
LDLC
rs4420638 0.30 0.36 ,0.01 0.34 6.3610
27 4.2610
23 0.19
0.19/0.20/0.20
19 APOCI (0) APOE (10) TOMM40 (16)
rs646776 0.04 0.92 ,0.01 0.04 3.7610
28 0.20 0.19
0.18/0.20/0.20
1 CELSR2 (0) PSRC1 (4) SORT1 (34)
rs7633531 0.13 0.84 ,0.01 0.03 1.4610
27 0.37 0.18
0.19/0.17/0.19
3 C3orf53 (211) ZCWPW2 (262) LOC131572 (300)
Triglyceride
rs1260326 ,0.01 0.83 ,0.01 0.17 5.0610
215 2.6610
22 0.45
0.46/0.44/0.45
2 GCKR (0) LOC729823 (11) FNDC4 (13)
rs964184 ,0.01 0.99 ,0.01 0.03 1.9610
214 0.46 0.14
0.14/0.14/0.14
11 ZNF259 (0) BUD13 (5) APOA5 (11)
rs9644568 0.06 0.90 ,0.01 0.04 4.5610
28 0.47 0.11
0.11/0.10/0.11
8 SLC18A1 (74) LPL (104) ATP6V1B2 (126)
rs1883025 0.35 0.63 ,0.01 0.02 6.4610
27 0.35 0.24
0.23/0.24/0.24
9 ABCA1 (0) NIPSNAP3B (128) NIPSNAP3A (142)
HDLC
rs247616 ,0.01 0.98 ,0.01 0.02 2.5610
232 0.45 0.32
0.32/0.32/0.33
16 CETP (6) HERPUD1 (12) SLC12A3 (42)
rs4775041 0.01 0.96 ,0.01 0.03 1.0610
28 0.86 0.25
0.26/0.24/0.26
15 LIPC (49) LOC441726 (181) AQP9 (197)
rs1011685 0.02 0.95 ,0.01 0.03 2.1610
28 0.58 0.12
0.12/0.12/0.13
8 LPL (6) INTS10 (121) SLC18A1 (172)
Table includes all regions with strong evidence for association with traits (posterior probability ,0.5 for no association). For each region, the SNP with the strongest
evidence for association is displayed. H0: null model; HS: sum model; HD: difference model; H(S+D): sum and difference model. SNPs associated with difference traits (HD
or H(S+D)) are in bold. P-values are uncorrected for multiple testing. Abbreviations: SNP, single nucleotide polymorphism; Diff., different trait; MAF, minor allele
frequency; Chr., chromosome.
*MAF listed for total population and then for each individual study (TNT/PRINCE/CAP).
doi:10.1371/journal.pone.0009763.t002
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difference phenotype D yielded a p-value of 1.9610
28. This SNP
was less strongly associated with change in LDLC (posterior
probability of association =0.16; P=3.9610
26). Examining this
SNP’s association with the TC difference trait separately within
each of the three studies, we observed the strongest association
signal in TNT (TNT P=1.2610
26; PRINCE P=4.8610
23; CAP
P=0.16, Table S2). On average across studies, carriers with two
copies of the minor allele of rs8014194 had 3.0% smaller
reductions in total cholesterol than did noncarriers, and variation
at rs8014194 explained 1% of the variance in statin-induced
changes in total cholesterol.
In addition, the Bayesian analysis yielded two other SNPs
showing moderate evidence for being associated with statin-
induced phenotype changes. The SNP rs4420638, located in the
APOC1 gene and near APOE, was assigned a 34% posterior
probability of association with statin-induced change in LDLC.
Variation at the APOE locus has been associated with statin-
mediated lipid response in several studies [4,13]. In addition
rs1260326 located in GCKR, was assigned a 17% probability of
being associated with statin-induced change in triglyceride. These
two putative SNP associations with response phenotypes were
highlighted much more strongly in the Bayesian analysis than in
the frequentist analysis. The p-values for associations with
difference traits of these 2 SNPs were 0.0042 and 0.026
respectively, which puts them well down the list of the top
associations. This difference in results between the two methods
occurred because both of these SNPs showed an appreciable
association with the sum trait, S. In this situation, the Bayesian
approach upweights such SNPs because it reinforces the idea that,
for a SNP associated with S, a modest association with D is more
likely to be genuine than it would be for a SNP that is unassociated
with S.
Besides the strongest associations reported here, there were
many more variants that showed non-trivial, although far from
conclusive, evidence for association with statin response. Two
variants were assigned between 10% and 50% probability of being
associated with statin-mediated changes in LDLC (Table S1B):
rs1431005 located on chromosome 4 (Posterior probability
=0.13, P=1.8610
27) and rs13390159 located on chromosome 2
(Posterior probability =0.17, P=2.1610
27). Both of these
variants were less strongly associated with total cholesterol change
(Table S1A) and both are located in genomic regions that contain
putative genes of unknown function. In addition, two SNPs were
assigned 10–50% probability of being associated with statin-
mediated change in triglyceride (Table S1C). The SNP rs7584099
was assigned a 22% posterior probability of association with statin-
induced change in triglyceride (p=5.4610
27). This SNP is located
124 Kb from the ACVR2A gene (activin A receptor, type IIA),
which is a serine/threonine kinase receptor that binds activin and
appears to play a role in cellular differentiation and proliferation
[34]. The SNP rs174583 was assigned a 10% posterior probability
of association with statin-induced change in triglyceride (p=0.01).
This SNP, located in the fatty acid desaturase (FADS) gene cluster
on chromosome 11 has been identified as strongly associated with
baseline triglycerides and HDLC in many studies and was
associated with HDLC within this study with a posterior
probability of 17% (P=6.8610
26, Table S1D) [12,31].
Finally, we identified some variants with less strong associations
that are near biologically plausible genes. For example, one of the
most significant associations with total cholesterol response was a
variant located on chromosome 2 near the gene encoding insulin
induced gene 2 (INSIG2). INSIG2 is involved in sterol-dependent
SREBP-mediated regulation of cholesterol metabolism and
INSIG2 has previously been identified within mouse models as a
susceptibility gene for total cholesterol [35,36]. Within this
genomic region, the strongest evidence was for association of
rs11673900, located 9 kb downstream of INSIG2 (Table S2A).
This SNP was assigned a 5% posterior probability of association
with statin-mediated change in total cholesterol (P=5.5610
26).
Discussion
The genetic contribution to variation in lipid-lowering response
to statin treatment appears to be influenced by multiple loci with
small individual contributions that are compounded when jointly
inherited. Although several loci have been identified in association
with statin efficacy using the candidate gene approach, the
combined contribution of these genotypes explains a relatively
small proportion of the variation in statin LDLC-lowering efficacy
[4,6]. GWA analysis of lipid-lowering response to statin treatment
has previously failed to identify novel loci [13] but the statistical
power to detect associations was limited by sample size. To address
this issue, we have performed a combined analysis on the three
statin GWA studies that are currently available. Because each of
the three trials tested a different statin, this analysis was specifically
designed to identify genetic variation that is associated with statin
class effects.
Among the associations identified by our analysis, the most
intriguing is the association of rs8014194 with changes in total
cholesterol in response to statin treatment. When we examined the
association between rs8014194 and change in total cholesterol
separately for each trial (TNT, PRINCE, CAP), we observed the
strongest association within TNT. While differential ability to
detect this association may reflect differences in statistical power
across these three studies based on sample size, it may also reflect
differences in pharmacological properties (e.g., dose response or
statin) or differences in biological mechanism (e.g., lipoprotein
homeostasis). This SNP was also less strongly associated with LDL-
Figure 1. Posterior probability of association with statin-
mediated difference trait for total cholesterol at chromosome
14 region. Gene structure indicated below graph. rs8014194, located
in CLMN intron 1, was the most significantly associated variant.
doi:10.1371/journal.pone.0009763.g001
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14 within intron 1 of the gene encoding calmin, CLMN. The
function of calmin is unknown but the protein sequence contains a
calponin-like binding domain that is expected to have actin-
binding activity [37]. Calmin is highly expressed in several tissues
including liver and adipose tissue [38]. Full-length calmin contains
a putative transmembrane domain and appears to be localized to
the endoplasmic reticulum [37]. Several CLMN alternative splice
variants encode isoforms that lack the transmembrane domain and
appear to be localized to the cytosol [37].
Calmin has not previously been implicated in cholesterol or
lipoprotein metabolism nor has CLMN variation been associated
with any metabolic traits. As a result it is natural to question
whether the observed association is likely to be genuine. Our
Bayesian analysis assessed the posterior probability of this
association being genuine to be 84%. This figure is sensitive to
prior assumptions about how likely each individual SNP is to be
associated with each statin response trait. Our analysis assumed
this to be 1 in 10
5, corresponding to an a priori assumption that
approximately 25 SNPs out of the 2.5 million tested would be
genuinely associated with statin response for each phenotype. The
data seem broadly consistent with this prior assumption, in that
the posterior expected number of such associations ranged from 19
(for HDLC) to 26 (for Tg). However, the data may also be
consistent with more conservative assumptions. If one were to
select a more conservative prior assumption of 1 in 5610
5
(implying approximately 5 genuinely associated SNPs) then the
posterior probability for rs8014194 being genuinely associated
with total cholesterol response decreases to approximately 50%.
Conversely, if one is less skeptical and increases the prior by a
factor of 4 (i.e. 100 genuinely-associated SNPs), the posterior
increases to over 95%. In a frequentist analysis, degree of
skepticism is reflected (implicitly or explicitly) in choice of
threshold for ‘‘genome-wide significance’’ [24,39]. In this case
the p-value for association, P=1.9610
28 meets conventional
levels for genome-wide significance – for example, it is nominally
significant at the 0.05 level after a Bonferroni correction for 2.5
million tests, and exceeds the 5610
27 threshold used by WTCCC
in reporting ‘‘strongly associated’’ variants [26]. Thus, there is
strong evidence to support the conclusion that rs8014194 is the
first novel SNP found through GWAS to be associated with statin
response, although definitive confirmation will depend on results
from additional statin pharmacogenomic trials. In addition, we
identified several SNPs with less strong evidence for association
with lipid response to statin treatment including 2 SNPs associated
with change in LDLC (posterior probabilities 13% and 17%)
located in genomic regions containing putative genes not known to
influence lipid metabolism, and 2 SNPs associated with change in
Tg including one near ACVR2A (posterior probability 22%) and
one within the FADS locus (posterior probability 10%).
One important issue facing any study of this nature is how to
define a ‘‘drug-response association’’. Naturally, any SNP that is
associated with only post-statin levels of the phenotype, and not
pre-statin levels, would be considered a drug-response association.
However, here we have broadened this definition to include any
SNP that has a different effect on average pre- and post- statin
phenotype levels. Note that this broader definition depends on the
scale on which phenotypes are considered. For example, if we had
used the raw scale for pre- and post-statin measures, then a SNP
that decreased pre-statin levels by 2 (units) on average and
decreased post-statin levels by the same average amount would not
count as a statin-response SNP. But if we had used the log-scale for
the measures, then the same SNP would become a response
association (effectively because 2 units is a different percentage of
the average post-statin than of the average pre-statin measures).
Our rank-based transformation procedures, which were used to
provide strong safeguards against spurious associations due to
potential differences in allele frequencies among studies, could
potentially complicate interpretation. However, since these rank-
based transformations produce phenotypes that are somewhat
similar to a log-transformation, we think of our definition of statin-
response associations as roughly encompassing SNPs that have a
different relative percentage reduction in pre- and post- statin lipid
levels. It is also important to note that these definitional subtleties
apply only to SNPs that affect both pre- and post- statin levels:
SNPs that affect one but not the other would satisfy the definition
of statin-response associations whatever scale is used. Nonetheless
it remains an open question to what extent SNPs that satisfy our
broader definition of statin-response associations have a molecular
interaction with the statins themselves, or the genetic pathways
they target – but this would be true of any definition, and the fact
that most previously-identified loci associated with untreated lipid
levels do not show a strong signal for statin-response associations
suggests that our definition is a reasonable starting point.
Another issue is whether there might be other, more effective,
statistical approaches to identifying statin response associations. It
has long been recognized that simply testing groups for association
with the change (Y2X) often has low power, because this change
generally has a high variance. Our analyses attempt to mediate
this problem by instead considering the bivariate outcome (X,Y),
or equivalently (Y2X,X+Y), to identify SNPs that are strongly
associated with pre- and/or post-statin lipid levels, and then,
among these SNPs, attempt to identify the subset of SNPs that
appear to have a different effect on Y than X. Intuitively this
bivariate approach should help when compared with simply
testing (Y2X) alone, because most SNPs that are genuinely
associated with (Y2X) are expected to be associated also with
Y+X. (e.g. SNPs associated with Y alone would fall into this
category). This bivariate approach is particularly helpful to
highlight SNPs for which there is complementary evidence for
association with both untreated and response traits, as illustrated
by the relatively high posterior probabilities assigned to SNPs near
APOE and GCKR in Table 2 for association with statin-related
change of LDLC and Tg, respectively. Another source of
information that one might incorporate into these analyses to
help improve power is the increasing amount of data from other
genetic association studies identifying SNPs associated with
untreated lipid levels [9,10,12,15,16,31]. Within our Bayesian
analysis this could be easily achieved by placing a much lower
prior probability on the null hypothesis H0 for these SNPs with
prior evidence for association. However, one could also incorpo-
rate this information into a frequentist analysis: to give just a
simple example, in a standard frequentist genome scan testing
SNPs for association with (Y2X), one could use a less stringent
significance threshold for those SNPs already known from other
studies to affect untreated lipid phenotype levels. Of course, choice
of appropriate threshold is a tricky problem, and one possible
reason to prefer the Bayesian approach.
The statistical approach we have taken here differs from that
taken in previous analysis of the TNT data [13], which tested for
association between genetic variants (G) and post-statin phenotype
measures (Y), controlling for pre-statin phenotype measures (X).
While this type of analysis, sometimes referred to as ANCOVA, is
standard for identifying group treatment effects in a randomized
controlled trial, it must be applied with caution in the setting of
genetic association studies. This is because this ANCOVA test is
aimed at rejecting the null hypothesis that Y is conditionally
independent of G given X, and rejecting this hypothesis in a
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associated with statin response. For example, if a genetic variant G
affects average pre- and post- statin lipid levels in the same way,
then by our definition it would not be a statin-response association,
but the ANCOVA test would tend to give a significant result. This
claim is easily verified by simulation (Figure S2 and File S1). Note
that the situation here is fundamentally different from a
randomized controlled trial, because the randomization is usually
designed to ensure that baseline measures (X) are unassociated
with the groups G being tested, in which case G will be associated
with the response (Y2X) if and only if it is associated with Y
controlling for X, and the ANCOVA test is preferred due to its
greater power [40]. This said, since one plausible type of statin-
response association is a SNP that is associated with Y and not X,
it would seem fruitful to take this into account in the analysis, and
with additional work this could be incorporated into our Bayesian
framework as an explicit additional hypothesis.
Finally regarding statistical methodology, we chose here to
perform a ‘‘fixed effects’’ combined analysis that assumes the effect
sizes are the same across studies, despite the fact that the studies
are clearly highly heterogeneous. We did this because we judged
that, due to limited sample size within each study, power would be
limited to detect any effects that did not appear consistent across
studies. Further, separate analyses of each study failed to yield
convincing evidence for loci with strong, but possibly different,
signals in more than one study. We note that although
heterogeneity across studies clearly results in model mis-specifica-
tion (and hence potential loss of power) under the alternative, the
null model remains unaffected by this heterogeneity (after our
normalization procedures ensuring that the phenotypes have the
same distribution in each study) and so, under the null,
heterogeneity should not cause false positive associations to be
detected by our analysis.
There were several limitations of this study. Because different
statins were tested in each of the three trials used for this combined
analysis, the results cannot be extrapolated to individual statins.
This may explain why no associations were observed with genes
involved in pharmacokinetic handling of statins. Separate analyses
of each study yielded no SNPs with high probability of being
associated with statin response phenotypes, presumably due to
limits in statistical power. There were also several major
differences in study populations across these trials, the major one
being the inclusion in PRINCE and TNT, but not CAP, of
individuals with documented CHD or CVD events. In addition,
untreated LDLC concentrations were higher in TNT than in CAP
or PRINCE, and this variation across study populations in
underlying CVD risk may influence genetic contribution to statin
response. Moreover, as noted above, to exclude individuals with
poor drug compliance, inclusion in TNT was limited to those who
achieved LDLC#130 mg/dL with atorvastatin treatment (4
weeks, 10 mg/day), and this likely led to underrepresentation of
genotypes associated with attenuated statin response. Although we
used imputation methods to maximize genomic coverage for these
analyses, this method is ultimately limited by the genomic
coverage of the underlying genotype panels. In particular,
variation at genomic regions with poor coverage, such as the
APOE locus, cannot be completely described through imputation.
Thus, the relatively modest posterior probability assigned to SNPs
near the APOE locus in this case may reflect the relatively small
number of individuals for whom genotypes were measured. In
addition, the SNPs at the HMG-CoA reductase (HMGCR) locus
that were identified in the PRINCE and CAP populations to be
associated with statin- mediated LDLC response [7,22] were not
genotyped in HapMap and, therefore, were not represented in this
analysis. Furthermore, rarer SNPs or haplotypes that may have
large effect sizes could not be assessed. Finally a major limitation is
the exclusion of individuals not of European ancestry. Although
we have incorporated all available published pharmacogenomic
studies of statin efficacy into our combined analysis, this study is
probably still underpowered and identification of variants with
statistically meaningful association to statin efficacy will require
analyses in expanded populations once GWA data from additional
trials becomes available. Despite this, results from this and other
studies suggest that no single SNP will describe more than ,3% of
the variance observed in lipid-lowering response to statin
treatment.
In summary, using Bayesian imputation-based analysis on a
combined population derived from the three currently available
statin GWA trials, we have identified a new candidate gene,
calmin, that may modulate statin-mediated changes in total
cholesterol and LDLC. This is the first report of a variant
associated with statin efficacy that was identified by GWAS and its
validation awaits functional analyses and replication in additional
statin trials.
Supporting Information
Figure S1 Q-Q plots for sum traits (A, total cholesterol; B, LDL-
cholesterol; C, HDL-cholesterol; D, triglyceride) and for difference
traits (E, total cholesterol; F, LDL-cholesterol; G, HDL-cholesterol;
H, triglyceride).
Found at: doi:10.1371/journal.pone.0009763.s001 (9.78 MB TIF)
Figure S2 Simulated illustration of behavior of the ANCOVA
test when applied to SNPs that have the same effect on both pre-
and post- exposure measurements. (A) histogram of p values from
the ANCOVA test. (B) histogram of p values from tests of the
difference Y-X against genotype (shown for comparison only, not
to advocate this test). The R code used to produce this Figure is
given in File S1 (Supplementary Methods). The non-uniform p
values in the top plot indicate that the ANCOVA test can tend to
give significant results for SNPs that affect both pre- and post-
exposure measures in the same way. As a result, a significant
ANCOVA test does not necessarily indicate a statin-dependent
association.
Found at: doi:10.1371/journal.pone.0009763.s002 (9.41 MB TIF)
File S1 Supplementary Methods: R code to do simulations to
illustrate that ANCOVA test can produce non-uniform p values
when a SNP has the same effect on both pre- and post- exposure
measurements as shown in Figure S2.
Found at: doi:10.1371/journal.pone.0009763.s003 (0.02 MB
DOC)
Table S1 Extended GWAS associations. For each trait (A, total
cholesterol; B, LDL-Cholsterol; C, HDL-Cholesterol; D, triglyc-
eride) the regions with moderate evidence for association (posterior
probability of 0.5 to 0.89 for the null hypothesis, H0) are
represented by the SNP within that region that showed the
strongest evidence for association. Associations with difference
traits are displayed in bold. H0: null model; HS: sum model; HD:
difference model; H(S+D): sum and difference model. Abbrevia-
tions: SNP, single nucleotide polymorphism; Diff., different trait;
MAF, minor allele frequency; Chr., chromosome.
Found at: doi:10.1371/journal.pone.0009763.s004 (0.11 MB
DOC)
Table S2 Single nucleotide polymorphisms (SNPs) associated
with difference or sum traits for total cholesterol with a posterior
probability greater than 1%. SNPs are listed by reference SNP
accession ID (rs#) and are ordered by chromosome number and
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by Bayesian analysis are listed for H0, HS, HD, HS+D followed by
p-values and effect sizes as calculated by frequentist statistics for
the sum and difference traits. Major and minor alleles are listed.
Abbreviations: MAF, minor allele frequency; chr, chromosome;
GENE1-3, genes closest to variant; dist1-3, distance of gene1-3 to
variant; log10BF, log(base 10) transformed bayes factor for: S, sum
trait in total population; S-TNT, sum trait in TNT population; S-
PRINCE, sum trait in PRINCE population; S-CAP, sum trait in
CAP population; D, difference trait in total population; D-TNT,
difference trait in TNT population; D-PRINCE, difference trait in
PRINCE population; D-CAP, difference trait in CAP population;
P-values from individual populations are also listed for each SNP.
A complete results list for all ,2.5 million sites is available online
at http://stephenslab.uchicago.edu/publications.html.
Found at: doi:10.1371/journal.pone.0009763.s005 (0.68 MB
XLS)
Table S3 Single nucleotide polymorphisms (SNPs) associated
with difference or sum traits for LDL-cholesterol with a posterior
probability greater than 1%. SNPs are listed by reference SNP
accession ID (rs#) and are ordered by chromosome number and
location on each chromosome. Posterior probabilities calculated
by Bayesian analysis are listed for H0, HS, HD, HS+D followed by
p-values and effect sizes as calculated by frequentist statistics for
the sum and difference traits. Major and minor alleles are listed.
Abbreviations: MAF, minor allele frequency; chr, chromosome;
GENE1-3, genes closest to variant; dist1-3, distance of gene1-3 to
variant; log10BF, log(base 10) transformed bayes factor for: S, sum
trait in total population; S-TNT, sum trait in TNT population; S-
PRINCE, sum trait in PRINCE population; S-CAP, sum trait in
CAP population; D, difference trait in total population; D-TNT,
difference trait in TNT population; D-PRINCE, difference trait in
PRINCE population; D-CAP, difference trait in CAP population;
P-values from individual populations are also listed for each SNP.
A complete results list for all ,2.5 million sites is available online
at http://stephenslab.uchicago.edu/publications.html.
Found at: doi:10.1371/journal.pone.0009763.s006 (0.67 MB
XLS)
Table S4 Single nucleotide polymorphisms (SNPs) associated
with difference or sum traits for HDL-cholesterol with a posterior
probability greater than 1%. SNPs are listed by reference SNP
accession ID (rs#) and are ordered by chromosome number and
location on each chromosome. Posterior probabilities calculated
by Bayesian analysis are listed for H0, HS, HD, HS+D followed by
p-values and effect sizes as calculated by frequentist statistics for
the sum and difference traits. Major and minor alleles are listed.
Abbreviations: MAF, minor allele frequency; chr, chromosome;
GENE1-3, genes closest to variant; dist1-3, distance of gene1-3 to
variant; log10BF, log(base 10) transformed bayes factor for: S, sum
trait in total population; S-TNT, sum trait in TNT population; S-
PRINCE, sum trait in PRINCE population; S-CAP, sum trait in
CAP population; D, difference trait in total population; D-TNT,
difference trait in TNT population; D-PRINCE, difference trait in
PRINCE population; D-CAP, difference trait in CAP population;
P-values from individual populations are also listed for each SNP.
A complete results list for all ,2.5 million sites is available online
at http://stephenslab.uchicago.edu/publications.html.
Found at: doi:10.1371/journal.pone.0009763.s007 (0.71 MB
XLS)
Table S5 Single nucleotide polymorphisms (SNPs) associated
with difference or sum traits for triglyceride with a posterior
probability greater than 1%. SNPs are listed by reference SNP
accession ID (rs#) and are ordered by chromosome number and
location on each chromosome. Posterior probabilities calculated
by Bayesian analysis are listed for H0, HS, HD, HS+D followed by
p-values and effect sizes as calculated by frequentist statistics for
the sum and difference traits. Major and minor alleles are listed.
Abbreviations: MAF, minor allele frequency; chr, chromosome;
GENE1-3, genes closest to variant; dist1-3, distance of gene1-3 to
variant; log10BF, log(base 10) transformed bayes factor for: S, sum
trait in total population; S-TNT, sum trait in TNT population; S-
PRINCE, sum trait in PRINCE population; S-CAP, sum trait in
CAP population; D, difference trait in total population; D-TNT,
difference trait in TNT population; D-PRINCE, difference trait in
PRINCE population; D-CAP, difference trait in CAP population;
P-values from individual populations are also listed for each SNP.
A complete results list for all ,2.5 million sites is available online
at http://stephenslab.uchicago.edu/publications.html.
Found at: doi:10.1371/journal.pone.0009763.s008 (0.92 MB
XLS)
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